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Abstract
Background: The aim of the study was to evaluate subcutaneous implantable cardioverter-defibrillator 
(S-ICD) patients with regard to underlying etiology, peri-procedural outcome, appropriate/inappropriate 
shocks, and complications during follow-up.
Methods: All patients who underwent S-ICD implantation from February 2013 to March 2017 at an 
academic hospital in Vienna were included. Medical records were examined and follow-up interroga-
tions of devices were conducted. 
Results: A total of 79 S-ICD patients (58.2% males) with a mean age of 44.5 ± 17.2 years were 
followed for a mean duration of 12.8 ± 13.7 months. A majority of patients (58.2%) had S-ICD for 
primary prevention of sudden cardiac death. The most common of the 16 underlying etiologies were 
ischemic cardiomyopathy, non-ischemic cardiomyopathy, and idiopathic ventricular fibrillation. The 
lead was implanted to the left sternal border in 96.2% of cases, between muscular layers in 72.2%. Mean 
implant time was 45 min, 3 patients were induced, and all patients except one were programmed to two 
zones. Six (7.6%) patients experienced at least one appropriate therapy for ventricular arrhythmias and 
the time to first event ranged from 1 to 52 months. Seven patients experienced inappropriate shocks due 
to T-wave oversensing, atrial tachycardia with rapid atrioventricular conduction, external electromag-
netic interference, and/or baseline oversensing due to lead movement. Four patients underwent revision 
for lead repositioning (n = 1), loose device suture (n = 1), and infection (n = 2).
Conclusions: While S-ICDs are a feasible and effective treatment, issues remain with inappropriate 
shock and infection. (Cardiol J 2019; 26, 5: 543–549)
Key words: arrhythmia, complication, subcutaneous implantable cardioverter- 
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Introduction
The entirely subcutaneous implantable cardio-
verter-defibrillator (S-ICD) offers an alternative 
to the transvenous/epicardial system in an effort 
to prevent sudden cardiac death. The advantages 
of implantation outside the thoracic cavity (Fig. 1) 
include: avoidance of cardiac complications (ar-
rhythmias, perforation, tricuspid valve damage), 
vessel-related problems (arterial puncture causing 
hematoma, venous thrombosis/obstruction), and tis-
sue damage (pneumothorax, nerve palsus, shoulder 
dysfunction) [1]. Only brief fluoroscopy is needed to 
verify proper lead placement. The defibrillator lead 
is more robust and is expected to provide better 
long-term outcomes than transvenous leads, which 
manifest a 20% failure rate over 10 years and which 
extraction (if necessary) can bring serious complica-
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tions, including death [2]. The use of an S-ICD is lim-
ited by its inability to provide antitachycardia pacing, 
cardiac resynchronization therapy, and bradycardia 
pacing, except for an immediate post-shock period; 
S-ICD systems are also comparatively expensive [1]. 
The pooled data from the landmark IDE and 
EFFORTLESS trials have proven the overall ef-
fectiveness of S-ICDs [3]. These promising results 
have been verified in external cohorts but further 
study in different settings is needed to justify more 
widespread use of S-ICD therapy [4–14].
The aim of this study was to evaluate patients 
who were implanted with an S-ICD at a tertiary 
center with regard to underlying etiology, peri-
procedural outcome, appropriate/inappropriate 
shocks, and complications during follow-up.
Methods
Setting
The complete records of all S-ICD implants 
at Allgemeine Krankenhaus Wien, a University 
Hospital in Vienna, Austria were extracted from the 
database of the Medical University of Vienna, De-
partment of Surgery, Division of Cardiac Surgery, 
Vienna, Austria. The first implant was performed 
in February, 2013 and the last in March, 2017. 
Data collection
Medical records were used to validate patient 
characteristics including the underlying etiol-
ogy and follow-up. All device interrogations were 
stored in the database provided by Boston Scientific 
and evaluated for appropriate and inappropriate 
shocks.
Ethics
The study complies with the Declaration of 
Helsinki and the local ethical committee approved 
the study.
Variables
An appropriate therapy was defined as detec-
tion of ventricular tachycardia (VT) or ventricular 
fibrillation (VF) and subsequent shock. Inappropri-
ate shocks were due to false classification of the 
arrhythmia (i.e. supraventricular tachycardias, 
oversensing of external signals, T-wave oversens-
ing, or baseline drift due to movement of the lead 
tip). Prophylaxis after surviving cardiac arrest/ 
/VF or VT with hemodynamic compromise was 
a secondary prevention. Patients with a primary 
prevention indication were judged to be at an 
increased risk for life-threatening ventricular 
arrhythmias but without having had one.
Figure 1. X-ray of the entirely subcutaneous implantable cardioverter-defibrillator system. Lead in the left sternal posi-
tion and device in the left mid-axillary line.
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Statistical analysis
Numeric data were expressed as frequencies, 
percentages, means, and percentiles. Continuous 
variables were summarized as means, standard 
deviations (SDs), percentiles, and compared using 
t-tests. Fisher’s test was used for categorical vari-
ables. A two-sided p-value of < 0.05 was consid-
ered statistically significant. The database in Excel 
2010 (Microsoft Corporation, Redmond, WA) was 
imported into SPSS version 22 (IBM, Armonk, NY).
Results
Patient characteristics
A total of 79 patients had an S-ICD implanted 
and were followed for a combined total of 1015 
months (84.6 years). The follow-up time ranged 
from 3 days (3 patients were lost to follow-up) to 
4.4 years, with a median of 7.0 months (mean 12.8 ± 
± 13.7 months). A majority were males (n = 46; 
58.2%). The median age at implant was 45 years 
(25th percentile 30 years and 75th percentile 
57 years); mean age was 44.5 ± 17.2 years with 
no significant sex difference (males 46.5 years and 
females 41.8 years; p = 0.217).
Coronary artery disease was diagnosed in 
21 (26.6%) patients and 11 (13.9%) patients had a his-
tory of atrial fibrillation at baseline or during follow-up. 
The underlying cardiac etiologies were cardiomyopa-
thy in 45 patients (ischemic, non-ischemic dilated, per-
ipartal, arrhythmogenic right ventricular, hypertroph-
ic, and Takotsubo cardiomyopathy), amyloidosis in 
1 patient, ion-channelopathies in 10 patients (Brugada 
syndrome and long QT syndrome), congenital disease 
in 5 patients (Ebstein’s anomaly, Duchenne muscular 
dystrophy, Carnitine transporter deficiency), acquired 
structural heart disease in 2 patients (sarcoidosis, 
myocarditis), and idiopathic VF or nonsustained VT 
with syncope in 16 patients. Each etiology category 
with regard to primary (n = 46; 58.2%) and second-
ary (n = 33; 41.8%) indication prevention is reported 
in Table 1. The most common cause of implant for 
men was ischemic cardiomyopathy followed by di-
lated cardiomyopathy and for women idiopathic VT/ 
/VF and ischemic cardiomyopathy, respectively. Sex 
distribution with regard to primary (males 65.2%; 
n = 30/46 and females 34.8%; n = 16/46) and sec-
ondary indication — 48.5% (n = 16/33) males and 
51.5% (n = 17/33) females which was not statistically 
different (p = 0.168).
Implant procedure
The subcutaneous lead was tunneled parallel 
to the left sternal border in 76 (96.2%) patients 
and the remaining 3 cases were tunneled to the 
right based on preimplant screening. The S-ICD 
device was implanted between the muscular layers 
in 57 (72.2%) patients versus above the pectoral 
fascia in 22 (27.8%) patients. Early in the study, the 
3-incision technique was sometimes used, but the 
2-incision technique was used more frequently as 
the study progressed (n = 55, 69.6%).
Although the manufacturer recommends de-
fibrillation threshold testing, it was performed in 
1 of 3 patients. In all 3 cases, VF could be success-
fully induced (idiopathic VF, long QT syndrome, 
and ischemic cardiomyopathy).
Both the mean and median procedure times 
(skin-to-skin) were 45 min when performed with-
out additional interventions such as bradycardia 
pacemaker implant, device extraction, epicardial 
leads, or concomitant tricuspid valve surgery.
Programming
With one exception, all patients had two-
zone programming. The lower zone was typically 
200 bpm but was set to 190 bpm in 1 patient and 
210 to 230 bpm in 14 patients, while the higher zone 
ranged 220–250 bpm. The primary vector was used 
in 57% (n = 45), second vector in 32.9% (n = 26), 
and alternative vector in 10.1% (n = 8) upon hos-
pital discharge. Notably, 10 patients switched from 
the primary to secondary vector after discharge, 
2 patients from second to first vector, and 1 patient 
from alternate to primary vector. In 3 patients, the 
zones were changed during follow-up. 
Appropriate shock
Six (7.6%) patients experienced at least one 
appropriate therapy of VT/VF. In one of these pa-
tients there was an additional appropriate therapy. 
The annual incidence was 8.3% (7 episodes during 
84.6 years, 83 events per 1000 years). In 6 out of 
7 episodes the VT/VF converted at first attempt 
but in one episode a second shock (with reversed 
polarity) was needed.
The underlying etiologies of the 6 patients 
were ischemic cardiomyopathy (n = 3), idiopathic 
VF (n = 2), and arrhythmogenic right ventricular 
cardiomyopathy (n = 1). In 5 of these patients the 
indication for the S-ICD was secondary prevention 
and in one, primary prevention. The time to first 
event ranged from 1 to 52 months.
Inappropriate shock and complications
Seven patients experienced inappropriate 
shocks due to T-wave oversensing, atrial tachy-
cardia with rapid atrioventricular conduction, 
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external electromagnetic interference, and base-
line oversensing of myopotentials due to lead 
movement (Table 2). Notably, in the 2 cases of 
baseline oversensing, the lead tip moved and they 
were both implanted using the two-incision tech-
nique (Table 1).
Four patients underwent revision of the S-ICD 
system. In 1 case lead position was checked on 
X-ray and deemed unacceptable. The incisions 
were closed so it had to be re-opened in order to 
reposition the lead. In another case, the device 
suture in the pocket ripped off and had to be re-
sewn. Furthermore, there were 2 cases of infection 
requiring explantation; 1 patient had no known risk 
factors for infection and the other was a diabetic 
on dialysis. One patient with severe amyloidosis 
died 2 months after implant but no post-mortem 
interrogation was performed.
Table 1. Underlying etiology and primary versus secondary indication of 79 patients with  
an subcutaneous implantable cardioverter-defibrillator (S-ICD).
Etiology Primary (n = 46) Secondary (n = 33) Total (n = 79)
Ischemic cardiomyopathy 16 6 22 (27.8%)
Non-ischemic dilated cardiomyopathy 7 4 11 (13.9%)
Peripartum cardiomyopathy 1 0 1 (1.3%)
Arrhythmogenic right ventricular cardiomyopathy 4 1 5 (6.3%)
Hypertrophic cardiomyopathy 4 1 5 (6.3%)
Takotsubo cardiomyopathy 0 1 1 (1.3%)
Amyloidosis 1 0 1 (1.3%)
Duchenne muscular dystrophy 1 0 1 (1.3%)
Carnitine transporter deficiency 0 1 1 (1.3%)
Ebstein’s anomaly 2 1 3 (3.8%)
Sarkoidosis 1 0 1 (1.3%)
Myocarditis 1 0 1 (1.3%)
Idiopathic ventricular fibrillation 0 15 15 (19.0%)
Idiopathic non-sustained ventricular tachycardia 1 0 1 (1.3%)
Long QT syndrome 3 3 6 (7.6%)
Brugada syndrome 4 0 4 (5.1%)
Table 2. Inappropriate subcutaneous implantable cardioverter-defibrillator (S-ICD) shocks: patient 
characteristics and causes.
Sex, age at shock Etiology Prevention Reason
Female, 51 years Idiopathic ventricular fibrillation Secondary T-wave oversening due to decreased  
R-wave and change in morphology
Male, 69 years Ischemic cardiomyopathy Primary Atrial tachycardia with rapid  
atrioventricular conduction
Female, 13 years Hypertrophic cardiomyopathy Secondary T-wave oversense due to decreased  
R-wave and change in morphology
Female, 31 years Idiopathic ventricular fibrillation Secondary Atrial tachycardia with rapid atrioventricular 
conduction after appropriate shock  
of ventricular tachycardia
Male, 41 years Cardiac sarcoidosis Primary External electromagnetic inference  
in the bathroom
Male, 18 years Long QT syndrome Secondary Oversensing of myopotentials due to  
lead movement (two incision technique)
Male, 54 years Ischemic cardiomyopathy Primary Baseline oversensing of myopotentials 
due to lead movement  
(two incision technique)
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Discussion 
This large sample confirms the age- and sex 
distribution of S-ICD reported in trials and other 
cohorts [3–14]. This is expected in a tertiary center 
sample where the underlying etiologies can vary 
and include rare diagnoses. 
The relatively young age of S-ICD cohorts 
may be explained by the fact that physicians may 
be more likely to recommend these devices to 
patients with long life expectancies, who are able 
to pay higher device costs, and who may want to 
avoid adding hardware to the vasculature.
The lower percentage of females has been 
noted in several S-ICD studies and this cohort 
shares this finding [3–14].
S-ICD therapy is effective
The 6 patients who experienced therapy were 
all converted in 7 episodes of VT/VF, which empha-
sizes the efficacy demonstrated by all major S-ICD 
cohorts [3–14]. This 7.6% proportion of patients 
during a mean follow-up of 12.8 months is in line 
with previous findings from diverse cohorts and 
the EFFORTLESS pooled data reported 5.3%, 
7.9%, and 11.8% at 1, 2, and 3 years cumulative 
incidence of first appropriate therapy, respectively 
[3]. However, it should be remembered that not 
every appropriate therapy is indeed lifesaving, as 
ventricular arrhythmias may be self-terminating. 
Based on the MADIT-RIT study of transvenous 
ICDs, antitachycardia pacing was delivered to 22% 
of patients with conventional programming, 8% 
with high-rate programming, and 4% with delayed 
programming. However there was no difference 
among these three groups over 1.4 years with 
respect to the rate of shock therapy [15].
In the S-ICD, the 18/24 interval is fixed and the 
time to therapy is longer than in transvenous-ICDs, 
with overall time to shock therapy being about the 
same as modern transvenous-ICD programming. 
Inappropriate shocks do occur  
but may be avoided
Seven (8.9%) patients were affected by inap-
propriate shocks. This is in the lower range of other 
reported S-ICD cohorts [3–14]. The pooled analy-
sis of IDE and EFFORTLESS registries reported 
13.1% inappropriate shocks at 3 years; notably, 
11.7% inappropriate shocks in dual-zone program-
ming and 20.5% in single-zone programming [3]. 
The dual-zone allows discrimination based on 
QRS morphology in order to prevent shock due 
to supraventricular tachycardias [16]. The lower 
incidence of inappropriate shocks in our cohort 
may be the result of adherence to manufacturer 
recommendations of prescreening and use of high-
specificity sensing algorithms for supraventricular 
tachycardias [16]. 
Hypertrophic cardiomyopathy patients may 
fail the prerequisite of providing a QRS and T-wave 
morphology template and, in fact, 15% of patients in 
another study were ruled ineligible for this reason 
[16, 17]. However, T-wave oversensing remains 
a problem (2 patients in the present study) and was 
the most frequently encountered reason (39%) for 
inappropriate shock in the EFFORTLESS registry 
[3] and its risk is increased with hypertrophic car-
diomyopathy [10]. There are ways to reduce the 
likelihood of T-wave oversensing, such as using 
exercise test settings and monitoring the repro-
gramming from secondary to primary (or alterna-
tive vector) configurations. T-wave oversensing 
is more likely with a low R/T ratio, bundle branch 
block, and repolarization abnormalities, which 
are most likely to occur during exercise [16]. 
A thorough preoperative screening is warranted 
and further improvement in the sensing algorithm 
would possibly decrease T-wave oversensing [18].
Different spectrum of complications
The EFFORTLESS registry reports a 6.4% 
(1.7% infections) implant-related complications re-
quiring surgical interventions during a mean follow-
up of 558 days. Interestingly, there seems to be 
a learning curve in S-ICD implantation technique sug-
gested by a decrease in complications over time [3].
Renal failure is prevalent in this population and 
is a known risk factor for infection in transvenous 
ICD recipients. In some S-ICD cohorts, 20% or 
more patients are on dialysis, a finding supported 
by a United States registry [19]. Note that com-
pared to transvenous leads, S-ICD leads may be 
extracted with less risk to the patient.
Even though vascular access is not needed, 
surgical skills are important for proper lead place-
ment and pocket formation. Intramuscular implant 
using blunt dissection in order to avoid skin erosion 
and discomfort [1, 20] is advocated herein. In the 
present cohort, mean implant time of 45 min was 
due to the fact that 96.2% of patients did not un-
dergo defibrillation testing. In a study by Winter et 
al. [20], the average implant time was 65 minutes.
The two-incision technique was performed 
in 69.6% and has previously been described [1]. 
Nevertheless, the 2 cases of inappropriate shocks 
due to baseline oversensing called for careful at-
tention in order to secure optimal long-term lead 
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placement (Fig. 2). This is similar to transvenous 
lead failure, which may impede appropriate shock 
but may also give rise to inappropriate shocks. 
Transvenous leads are susceptible to complica-
tions not only during implant but, unfortunately, 
increasingly so over time [2]. While there is still 
a risk of infection with an S-ICD system, endocarditis 
and myocardial/vessel damage may be ruled out. 
For this reason, an S-ICD may be a good choice 
for patients who had to have a transvenous ICD 
extracted due to infection.
Strengths and weaknesses
This study supports the use of S-ICD in se-
lected patients who are at risk for sudden cardiac 
death, but short follow-up time remains a major 
limitation. To further compare S-ICD systems 
with transvenous ICDs, randomized controlled 
trials are needed to overcome the limitations of 
comparisons using historical cohorts or matched-
controlled groups with heterogeneity in etiology, 
age, and comorbidities. 
Conclusions
This patient cohort from a single tertiary 
center demonstrates the implant feasibility and 
therapeutic efficacy of the S-ICD, but inappropriate 
shocks and infection remain problems.
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Figure 2. Inappropriate subcutaneous implantable cardioverter-defibrillator (S-ICD) shock due to baseline oversens-
ing caused by lead movement (two-incision technique).
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